Printed From:

Praluent (alirocumab) is subject to additional monitoring. This will allow quick identification of new safety information.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side-effects not listed in the Praluent package leaflet. You can also tell us about side-effects through the Yellow Card Scheme at

Side-effects may also be reported to the Sanofi Drug Safety Department on 01483 554242 or by email to